Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2

Completed

Conditions studied: Heparin-induced Thrombocytopenia

In brief

The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.

Key facts

Study ID

NCT02526485

Run by

Vanderbilt University Medical Center

People needed

15

Starts

2015-03-01

Expected to finish

2018-09-05

Last updated by the study team

2020-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Ability to give informed consent
• Participants with heparin/PF4 antibody and SRA testing for HIT, including: participants with negative heparin/PF4 antibodies and negative SRA (controls), participants with positive heparin/PF4 antibodies and negative SRA (seroconversion cases), and participants with positive heparin/PF4 antibodies and positive SRA (HIT cases)
• Treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) within 7 days of blood draw

You may not qualify if…

• Less than 18 years of age
• Inability to give informed consent

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.